Tanja Obradovic

Dr. Tanja Obradovic has over 20 years of experience in Oncology pharmaceutical development. Her work encompasses all stages of clinical development and medical affairs gained from holding senior positions at Merck where she significantly contributed to Keytruda development, regulatory approvals and life cycle management across tumor types including melanoma, lung, women’s cancers and many other indications for over 10 years. Most recently she was leading development of drug and cell therapies at Takeda followed by leadership in oncology strategic drug development as VP of Drug Development Services, Scientific Affairs within Medical Strategy at ICON. She is currently on Advisory Boards for several Biotech companies and Consultant at Arc Nouvel Clinical Development LLC.